explore -WSS

explore

author：explore 2025-09-27 23:00:23 - browse：85

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Truvian presents data for its desktop blood

WSS

How doctors’ personal politics affect patients

In the gardens at Boston Children's Hospital, families find sanctuary

Former reverend arrested for allegedly killing 8

Obesity drug from Roche shows promise in early study

Galapagos to make CAR

Free medical tuition alone isn't enough to close gaps in primary care

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Bright Health sells Medicare Advantage business to Molina

Biden warns of ‘dark winter’ during final presidental debate

Psychedelics group wrestles with new pharma identity

CVS is willing to dump 10% of its Medicare Advantage members

Wildfire smoke exposes gaps in outdoor worker protections

The United States must get value

At least 13 dead in Texas as scorching temps continue

Novo Nordisk testing Wegovy against alcohol

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

leisure time

What it's like to live with paralysis for one psychologist

ALS treatment from Biogen, Ionis fails in study

The battle over 'scope creep' and who gets to be called 'doctor'

Novo Nordisk testing Wegovy against alcohol

ALS treatment from Biogen, Ionis fails in study

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

leisure time

entertainment

hotspot

leisure time